Health workers an Ebola treatment facility run by Médecins Sans Frontières (MSF) in Guéckédou, Guinea. (Credit: Ari Gaitanis/un_photo/Flickr)

Ebola

Targeting semen proteins may stop Ebola spreading via sex

Protein fragments in human semen called amyloid fibrils significantly increase Ebola virus infection and protect the virus against harsh environmental conditions such as heat and dehydration, according to new research.

Although Ebola is transmitted primarily through direct contact with blood and other bodily fluids from infected people, follow-up studies from the 2014 epidemic found that men can harbor the virus in their semen for at least 2.5 years, with the potential to transmit the virus sexually during that time.

The researchers surmise that targeting amyloids in semen could prevent a sexually transmitted spread of the virus.

“Sexual transmission of the Ebola virus poses a significant public health concern, especially in light of the ongoing Ebola outbreak in the Democratic Republic of the Congo,” says senior author Paul Bates, a professor of microbiology at the University of Pennsylvania and senior author of the paper, which appears in the Proceedings of the National Academy of Sciences.

Sexual transmission has also been linked to a resurgence of the virus in Guinea, which had previously been declared Ebola-free during the West Africa Ebola outbreak. However, the role of host factors involved in sexual transmission remains poorly understood.

Strategies for countering amyloids, such as creating small molecules that disrupt its structure, have been developed to slow or halt HIV transmission. The researchers suggest that this approach could be tested for its ability to reduce infection in models of Ebola sexual transmission.

Several types of amyloids found in semen enhance the transmission and infection of other viruses, such as HIV, by helping the virus attach to the membrane surrounding host cells.

In a previous study, coauthor James Shorter, an associate professor of biochemistry and biophysics, identified how yeast heat shock proteins and a small molecule called CLR01 could disrupt the formation of amyloid fibrils found in semen to make human immune cells less likely to be infected with HIV.

Stephen Bart, a postdoctoral fellow in the Bates lab and first author of the new study, applied what he learned on the HIV study to investigate the details of sexual transmission of the Ebola virus.

To test the ability of amyloids to enhance infection, researchers incubated benign viruses with the distinctive Ebola glycoprotein (a marker on the outside of the virus particle) with physiological concentrations of semen amyloids before infecting a variety of human cell types including macrophages, a primary target of Ebola virus in humans. Infection levels of cells with this benign Ebola virus and amyloids were about 20 times higher compared to cells with the virus alone.

What’s going on with the latest Ebola outbreak?

Coauthors Courtney Cohen and John M. Dye from the Virology Division of the US Army Medical Research Institute of Infectious Diseases found similar results using live Ebola in Biosafety Level 4 facilities in Frederick, Maryland.

The team also found that amyloids enhanced the binding of the virus to cells and increased its ability to be internalized by host cells. The fibrils working within semen significantly altered the physical properties of the virus, making it better able to survive in internal body environments of high temperature and less moisture.

“Given the potential for sexual transmission to spark new Ebola infection chains, we feel we have found relevant factors that may be important targets for inhibiting the spread of Ebola,” Bart says.

The team’s next steps are to determine if the amyloids have an effect on the virus in models of vaginal infection and if compounds that disrupt the amyloids are protective. Additionally, they plan to analyze amyloids found in other sites, such as the human gut, to see if they play a role in other types of viral infections.

Ebola RNA lingers in semen longer than expected

The National Institutes of Health, the Bill and Melinda Gates Foundation Grand Challenges Explorations Award, the Defense Threat Reduction Agency, and the Department of Defense Peer Reviewed Medical Research Program Grant funded the work.

Source: Penn

Related Articles